

Status: Currently Official on 17-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-A5307622-76D9-44E7-9470-4CF708634257\_4\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M87770\\_04\\_01](https://doi.org/10.31003/USPNF_M87770_04_01)  
 DOI Ref: nm7un

© 2025 USPC  
 Do not distribute

# Vancomycin Hydrochloride for Injection

## DEFINITION

Vancomycin Hydrochloride for Injection is a sterile dry mixture of Vancomycin Hydrochloride and may contain a suitable stabilizing agent. It contains NLT 90.0% and NMT 115.0% of the labeled amount of vancomycin.

## IDENTIFICATION

### Change to read:

- ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197K](#) ▲ (CN 1-MAY-2020)

## ASSAY

- [ANTIBIOTICS—MICROBIAL ASSAYS \(81\)](#)

**Sample solution 1** (where it is represented as being in a single-dose container): Constitute a container of Vancomycin Hydrochloride for Injection in water corresponding to the volume of diluent specified in the labeling. Withdraw all of the withdrawable contents, using a suitable hypodermic needle and syringe. Dilute to an equivalent of 1 mg/mL of vancomycin with water.

**Sample solution 2** (where it is packaged for dispensing): Dissolve the contents of 1 container of Vancomycin Hydrochloride for Injection in water, and dilute with water to obtain a solution having a concentration of 1 mg/mL of vancomycin.

**Sample solution 3** (where the label states the quantity of vancomycin in a given volume of constituted solution): Constitute a container of Vancomycin Hydrochloride for Injection in water corresponding to the volume of diluent specified in the labeling. Dilute a portion to obtain a final concentration equivalent to 1 mg/mL of vancomycin in water.

**Analysis:** Proceed as directed in [Antibiotics—Microbial Assays \(81\)](#). [NOTE—Use a measured volume of the appropriate *Sample solution*, diluted quantitatively with *Buffer B.4* to yield a *Test Dilution* having a concentration assumed to be equal to the median dose level of the Standard.]

**Acceptance criteria:** 90.0%–115.0%

## PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements

## SPECIFIC TESTS

- [PARTICULATE MATTER IN INJECTIONS \(788\)](#): Meets the requirements under small-volume injections
- [BACTERIAL ENDOTOXINS TEST \(85\)](#): NMT 0.33 USP Endotoxin Unit/mg of vancomycin
- [STERILITY TESTS \(71\)](#): It meets the requirements when tested as directed for [Test for Sterility of the Product to Be Examined, Membrane Filtration](#), except to dissolve the specimen in water instead of in *Fluid A*.
- [pH \(791\)](#): 2.5–4.5, 50 mg/mL in water
- [WATER DETERMINATION, Method I \(921\)](#): NMT 5.0%
- [INJECTIONS AND IMPLANTED DRUG PRODUCTS \(1\)](#), [Specific Tests, Completeness and clarity of solutions](#): Meets the requirements at the time of use.

### CONTENT OF VANCOMYCIN

**Solution A:** Triethylamine and water (1:500). Adjust with phosphoric acid to a pH of 3.2.

**Solution B:** Acetonitrile, tetrahydrofuran, and *Solution A* (7:1:92)

**Solution C:** Acetonitrile, tetrahydrofuran, and *Solution A* (29:1:70)

**Mobile phase:** See the gradient table below.

[NOTE—Make adjustments if necessary, changing the acetonitrile proportion in *Solution B* to obtain a retention time of 7.5–10.5 min for the main vancomycin peak.]

Time (min)	Solution B (%)	Solution C (%)
0	100	0

Time (min)	Solution B (%)	Solution C (%)
12	100	0
20	0	100
22	0	100
23	100	0
30	100	0

**System suitability solution:** 0.5 mg/mL of [USP Vancomycin Hydrochloride RS](#). Heat at 65° for 48 h, and allow to cool.

**Sample solution 1:** Equivalent to 10 mg/mL of vancomycin from Vancomycin Hydrochloride for Injection in *Solution B*

**Sample solution 2:** 0.4 mg/mL of vancomycin from *Sample solution 1* in *Solution B*

**Chromatographic system**

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 280 nm

**Column:** 4.6-mm × 25-cm; 5-µm packing L1

**Flow rate:** 2 mL/min

**Injection size:** 20 µL

**System suitability**

**Sample:** *System suitability solution*

[NOTE—The elution order is compound 1, vancomycin B, and compound 2. Compound 2 elutes 3–6 min after the start of the period when the percentage of *Solution C* increases from 0% to 100%.]

**Suitability requirements**

**Resolution:** NLT 3.0 between compound 1 and vancomycin B

**Column efficiency:** NLT 1500 theoretical plates, calculated from the vancomycin B peak

**Analysis**

**Samples:** *Sample solution 1* and *Sample solution 2*

[NOTE—Where baseline separation is not achieved, peak areas are defined by vertical lines extended from the valleys between peaks to the baseline. The main component peak may include a fronting shoulder, which is attributed to monodechlorovancomycin. This shoulder should not be integrated separately.]

[NOTE—Correct any peak observed in the chromatograms obtained from *Sample solution 1* and *Sample solution 2* by subtracting the area response of any peak observed in the chromatogram of *Solution B* at the corresponding elution time.]

Measure the area responses for all of the peaks.

Calculate the percentage of vancomycin B in the specimen tested:

$$\text{Result} = [D \times r_B / ((D \times r_B) + r_A)] \times 100$$

D = dilution factor, *Sample solution 1* to *Sample solution 2*, 25

r<sub>B</sub> = corrected area response of the main peak from *Sample solution 2*

r<sub>A</sub> = sum of the corrected area responses of all the peaks, other than the main peak, from *Sample solution 1*

Calculate the percentage of each other peak taken:

$$\text{Result} = \{r_i / [(D \times r_B) + r_A]\} \times 100$$

r<sub>i</sub> = corrected area response of any individual peak, other than the main peak, from *Sample solution 1*

D = dilution factor, *Sample solution 1* to *Sample solution 2*, 25

**Acceptance criteria:** NLT 80.0% of vancomycin B; NMT 9.0% of any peak other than the main peak

• **OTHER REQUIREMENTS:** It meets the requirements under [Injections and Implanted Drug Products \(1\)](#).

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve as described in [Packaging and Storage Requirements \(659\)](#), [Injection Packaging](#), [Packaging for constitution](#).
- **LABELING:** Meets the requirements under [Labeling \(7\)](#), [Labels and Labeling for Injectable Products](#)
- **USP REFERENCE STANDARDS (11)**  
[USP Vancomycin Hydrochloride RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
VANCOMYCIN HYDROCHLORIDE FOR INJECTION	<a href="#">Ying Han</a> Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	BIO42020 Biologics Monographs 4 - Antibiotics

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 35(4)

**Current DocID:** [GUID-A5307622-76D9-44E7-9470-4CF708634257\\_4\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M87770\\_04\\_01](https://doi.org/10.31003/USPNF_M87770_04_01)

**DOI ref:** [nm7un](#)

OFFICIAL